Monitor mid-2026 topline data from ongoing trials as the next major catalyst; current financials reflect investment phase with no near-term profitability, but cash runway supports development without immediate dilution risk.
SION drugs
SION drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $33.92entry
- T+1 · 9mo ago +0.50%α +1.42% · $34.09
- T+5 · 8mo ago +10.64%α +11.85% · $37.53
- T+20 · 8mo ago +8.08%α +16.02% · $36.66
- T+60 · 6mo ago +26.42%α +17.09% · $42.88
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sionna Therapeutics reported financial results for Q4 and full year 2025, highlighting increased R&D and G&A spending, a growing net loss, and a strong cash position of $310.3 million that funds operations into 2028. The company advanced its NBD1 stabilizer pipeline with Phase 1/2a trials on track for mid-2026 readouts, but no revenue-generating products or positive clinical outcomes were reported.
Key Financial Metrics
Key Facts
- No revenue generated; biopharma company in clinical stage with no commercial products
- Net loss increased to $75.3 million in 2025 from $61.7 million in 2024
- Cash and equivalents totaled $310.3 million as of December 31, 2025, up from $168.0 million in 2024
- SION-719 and SION-451 Phase 1 trials completed with topline data expected mid-2026
- R&D expenses rose to $60.3 million in 2025 from $57.3 million in 2024
- G&A expenses nearly doubled to $28.7 million in 2025 from $13.3 million in 2024
Financial Impact
Increased operating losses and higher G&A due to growth initiatives; cash runway extended to 2028
Risk Factors
- Clinical trial failure risk for SION-719 and SION-451 in mid-2026 readouts
- Increasing net losses and lack of revenue may pressure valuation if trials underperform
- Heavy reliance on successful development of unproven NBD1 stabilizer mechanism
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247220 |
Track record
22 reports on SION
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $3.70 Now $3.12 −15.68% settles Nov 17
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
- Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
- Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
- Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
- Aug 6, 202614w ago 8-K Neutral 4/10 Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
- Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
- Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers